TY - JOUR
T1 - Clinical characteristics of clear cell ovarian cancer
T2 - A retrospective multicenter experience of 308 patients in South Korea
AU - Lee, Hee Yeon
AU - Hong, Ji Hyung
AU - Byun, Jae Ho
AU - Kim, Hee Jun
AU - Baek, Sun Kyung
AU - Kim, Jin Young
AU - Kim, Ki Hyang
AU - Yun, Jina
AU - Kim, Jung A.
AU - Park, Kwonoh
AU - Lee, Hyo Jin
AU - Lee, Jung Lim
AU - Won, Young Woong
AU - Kim, Il Hwan
AU - Bae, Woo Kyun
AU - Park, Kyong Hwa
AU - Sun, Der Sheng
AU - Lee, Suee
AU - Lee, Min Young
AU - Lee, Guk Jin
AU - Hong, Sook Hee
AU - Jung, Yun Hwa
AU - An, Ho Jung
N1 - Publisher Copyright:
© 2020 by the Korean Cancer Association
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Purpose The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage. Materials and Methods Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected. Results Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease < 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence. Conclusion Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.
AB - Purpose The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage. Materials and Methods Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected. Results Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease < 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence. Conclusion Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.
KW - Adjuvant chemotherapy
KW - Clear cell adenocarcinoma
KW - Korea
KW - Ovarian epithelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85077934315&partnerID=8YFLogxK
U2 - 10.4143/crt.2019.292
DO - 10.4143/crt.2019.292
M3 - Article
C2 - 31319640
AN - SCOPUS:85077934315
SN - 1598-2998
VL - 52
SP - 277
EP - 283
JO - Cancer Research and Treatment
JF - Cancer Research and Treatment
IS - 1
ER -